Literature DB >> 17116666

Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.

Klaudia Kosowska-Shick1, Kim L Credito, Glenn A Pankuch, Bonifacio DeWasse, Pamela McGhee, Peter C Appelbaum.   

Abstract

LBM415 is a peptide deformylase inhibitor active against gram-positive bacterial species and some gram-negative species. In multiselection studies, LBM415 had low MICs against all Streptococcus pneumoniae strains tested, regardless of their genotype, and selected resistant clones after 14 to 50 days. MIC increases correlated with changes mostly in the 70GXGXAAXQ77 motif in peptide deformylase. The postantibiotic effect of LBM415 ranged from 0.3 to 1.4 h.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17116666      PMCID： PMC1797776          DOI： 10.1128/AAC.01150-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  Antimicrobial spectrum and activity of NVP PDF-713, a novel peptide deformylase inhibitor, tested against 1,837 recent Gram-positive clinical isolates.

Authors:  Ronald N Jones; Thomas R Fritsche; Helio S Sader
Journal:  Diagn Microbiol Infect Dis       Date:  2004-05       Impact factor: 2.803

2.  Single and multi-step resistance selection study in Streptococcus pneumoniae comparing ceftriaxone with levofloxacin, gatifloxacin and moxifloxacin.

Authors:  Frederick A Browne; Cathy Clark; Bülent Bozdogan; Bonifacio E Dewasse; Michael R Jacobs; Peter C Appelbaum
Journal:  Int J Antimicrob Agents       Date:  2002-08       Impact factor: 5.283

3.  Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae.

Authors:  Annie Canu; Brigitte Malbruny; Maëlle Coquemont; Todd A Davies; Peter C Appelbaum; Roland Leclercq
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

4.  In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae.

Authors:  K Nagai; T A Davies; G A Pankuch; B E Dewasse; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

5.  An unmodified heptadecapeptide pheromone induces competence for genetic transformation in Streptococcus pneumoniae.

Authors:  L S Håvarstein; G Coomaraswamy; D A Morrison
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

6.  Resistance of Streptococcus pneumoniae to deformylase inhibitors is due to mutations in defB.

Authors:  P Margolis; C Hackbarth; S Lopez; M Maniar; W Wang; Z Yuan; R White; J Trias
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

7.  Antipneumococcal activities of two novel macrolides, GW 773546 and GW 708408, compared with those of erythromycin, azithromycin, clarithromycin, clindamycin, and telithromycin.

Authors:  Vlatka Matic; Klaudia Kosowska; Bulent Bozdogan; Linda M Kelly; Kathy Smith; Lois M Ednie; Gengrong Lin; Kim L Credito; Catherine L Clark; Pamela McGhee; Glenn A Pankuch; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

8.  Antipneumococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.

Authors:  Lois M Ednie; Glenn Pankuch; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

9.  Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates.

Authors:  Ronald N Jones; Gary J Moet; Helio S Sader; Thomas R Fritsche
Journal:  J Antimicrob Chemother       Date:  2004-03-31       Impact factor: 5.790

10.  Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).

Authors:  Amy A Watters; Ronald N Jones; Jennifer A Leeds; Gerald Denys; Helio S Sader; Thomas R Fritsche
Journal:  J Antimicrob Chemother       Date:  2006-03-20       Impact factor: 5.790
View more
  5 in total

1.  Mutations in three distinct loci cause resistance to peptide deformylase inhibitors in Bacillus subtilis.

Authors:  Yann Duroc; Carmela Giglione; Thierry Meinnel
Journal:  Antimicrob Agents Chemother       Date:  2009-01-26       Impact factor: 5.191

2.  Multistep resistance development studies of ceftaroline in gram-positive and -negative bacteria.

Authors:  Catherine Clark; Pamela McGhee; Peter C Appelbaum; Klaudia Kosowska-Shick
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

3.  Frequency of Spontaneous Resistance to Peptide Deformylase Inhibitor GSK1322322 in Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes, and Streptococcus pneumoniae.

Authors:  Sharon Min; Karen Ingraham; Jianzhong Huang; Lynn McCloskey; Sarah Rilling; Anne Windau; Jason Pizzollo; Deborah Butler; Kelly Aubart; Linda A Miller; Magdalena Zalacain; David J Holmes; Karen O'Dwyer
Journal:  Antimicrob Agents Chemother       Date:  2015-05-26       Impact factor: 5.191

4.  In vitro capability of faropenem to select for resistant mutants of Streptococcus pneumoniae and Haemophilus influenzae.

Authors:  Klaudia Kosowska-Shick; Catherine Clark; Kim Credito; Bonifacio Dewasse; Linda Beachel; Lois Ednie; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2007-12-17       Impact factor: 5.191

5.  Drug forecast - the peptide deformylase inhibitors as antibacterial agents.

Authors:  David R P Guay
Journal:  Ther Clin Risk Manag       Date:  2007-08       Impact factor: 2.423
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.